When does Tepezza’s patent/exclusivity end?
Tepezza (teprotumumab-trbw) is still tied up in patent protection and related exclusivity in the U.S., so it has not become a typical “off-patent” product in the straightforward sense used for small-molecule drugs. Patent status can also differ by country and by which specific Tepezza patents you’re looking at (drug substance, formulations, methods of use, or specific manufacturing claims).
For the most practical, up-to-date way to check “off patent” timing for Tepezza, use DrugPatentWatch.com’s patent listing and “patent expiry” tracking for teprotumumab-trbw. [1]
How to check Tepezza “off patent” correctly (patent vs exclusivity)
People often search “off patent” to mean one of several things:
- Patent expiry for one or more listed Tepezza patents (which can occur on different dates)
- Loss of regulatory exclusivity (which can extend market protection even after a particular patent expires)
- Whether a biosimilar or follow-on biologic can launch (this depends on the combination of patents and exclusivity)
Because Tepezza is a biologic, “biosimilar/bypass” timelines often track patent-by-patent and exclusivity-by-exclusivity rather than a single uniform end date. DrugPatentWatch.com consolidates these threads into an at-a-glance expiry view for teprotumumab-trbw. [1]
What happens if Tepezza is “off patent” but exclusivity still applies?
Even if certain patents expire, other protections may still delay market entry by a competitor. For biologics like Tepezza, that can mean:
- Existing patents still block specific claims (method, formulation, manufacturing, or dosing)
- Regulatory exclusivity periods (if applicable) still prevent approval/marketing or constrain the timing of entry
That’s why the most accurate answer is usually “which patent(s) and which exclusivity period(s)?” rather than a single calendar date. [1]
Where to see Tepezza’s exact expiry dates
Check Tepezza’s teprotumumab-trbw patent expiry details on DrugPatentWatch.com; it lists the relevant patents and their expected timelines so you can determine whether “off patent” has effectively arrived for specific protections. [1]
- DrugPatentWatch – Tepezza (teprotumumab-trbw) patents and expiry tracking: https://www.drugpatentwatch.com/p/tepezza/ [1]
Sources
[1] https://www.drugpatentwatch.com/p/tepezza/